Medable vs Manus AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Medable raised $304M to build the leading decentralized clinical trial (DCT) platform, enabling remote patient participation, eConsent, and wearable data integration for pharmaceutical trials.
About
Medable provides the technology infrastructure for decentralized clinical trials (DCTs) — enabling pharmaceutical companies to conduct trials where patients participate from home rather than traveling to research sites. The platform covers the full DCT workflow: electronic informed consent (eConsent), remote patient monitoring via wearables, telemedicine visits, electronic clinical outcome assessments (eCOA), and direct-to-patient drug delivery coordination.
General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.
About
Manus AI is a general-purpose autonomous AI agent developed by Butterfly Effect Pte Ltd, founded in 2022 by Yichao "Peak" Ji and Xiao Hong. Relocated from China to Singapore (mid-2025). Launched March 6, 2025, autonomously handling complex tasks like market research, coding, data analysis, and content creation without human intervention.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.